RVNC
Revance Therapeutics, Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$381.02M
P/E Ratio
—
EPS
$-3.34
Beta
0.95
52W High
$0.00
52W Low
$0.00
50-Day MA
$3.39
200-Day MA
$4.16
Dividend Yield
—
Profit Margin
-71.80%
Forward P/E
—
PEG Ratio
-0.64
About Revance Therapeutics, Inc.
Revance Therapeutics, Inc., a biotechnology company, is dedicated to the development, manufacture, and marketing of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company is headquartered in Newark, California.
Fundamentals
| Revenue (TTM) | $256.94M |
| Gross Profit (TTM) | $103.69M |
| EBITDA | $-187.62M |
| Operating Margin | -53.90% |
| Return on Equity | -2097.00% |
| Return on Assets | -24.40% |
| Revenue/Share (TTM) | $2.66 |
| Book Value | $-1.55 |
| Price-to-Book | 12.30 |
| Price-to-Sales (TTM) | 1.48 |
| EV/Revenue | 2.648 |
| EV/EBITDA | -2.26 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 10.70% |
| Shares Outstanding | $104.39M |
| Float | $91.29M |
| % Insiders | 8.56% |
| % Institutions | 87.45% |
Historical Volatility
HV 10-Day
0.00%
HV 20-Day
0.00%
HV 30-Day
0.00%
HV 60-Day
0.00%
HV Rank
—
Volatility is currently contracting
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on RVNC and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 7/29/2026